Highlights NextCell Pharma AB

Equities

NXTCL

SE0009723125

Market Closed - Nasdaq Stockholm Other stock markets 08:59:48 28/05/2024 pm IST			5-day change	1st Jan Change
3.8 ^SEK	+114.69%		+181.48%	+44.49%

27/05	Nextcell Pharma AB Elects Hans-Peter Ekre as New Chairman of the Board	CI
25/04	NextCell Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

NextCell Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	25/04	CI
NextCell Pharma AB Announces Swedish Health and Social Care Inspectorate Grants Their Cellaviva Tissue Establishment Permission to Handle Amniotic Tissue	22/04	CI
The Swedish Medical Products Agency Approves Subgroup Analysis in NextCell Pharma AB's ProTrans-Young study	27/03	CI
NextCell Pharma AB Establishes QVance to Meet the Nordic's Need for Quality Analytics	14/03	CI
NextCell Pharma AB Reports Earnings Results for the First Quarter Ended November 30, 2023	25/01	CI
Nextcell Pharma Announces Updates Regarding Nextcell's Clinical Trials with Protrans	24/01	CI
NextCell Pharma AB Announces Repeated Treatment with ProTrans Is Immunologically Safe	06/11	CI
NextCell Pharma AB Reports Earnings Results for the Full Year Ended August 31, 2023	26/23/26	CI
NextCell Pharma AB Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	26/23/26	CI
Nextcell Pharma, Lino Signs Distribution Deal in Sweden	10/23/10	MT
Nextcell Pharma AB Signs an Agreement for A New Tissue Product with Linio	10/23/10	CI
NextCell Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	27/23/27	CI
NextCell Pharma AB Announces Treatment Start of Severe Pneumonia with High Dose of ProTrans	05/23/05	CI
NextCell Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	27/23/27	CI
FDA Approves a Product of Multiplied Stem Cells from Umbilical Cord Blood of NextCell Pharma AB	26/23/26	CI
Nextcell Pharma AB Publishes the Phase I/II Clinical Trial in Type I Diabetes Accepted	28/23/28	CI
NextCell Pharma AB Reports Earnings Results for the First Quarter Ended November 30, 2022	26/23/26	CI
NextCell Pharma AB Announces First Pediatric Patients Treated with ProTrans in Type-1 Diabetes Phase II Study	21/22/21	CI
NextCell Pharma AB Reports Earnings Results for the Full Year Ended August 31, 2022	03/22/03	CI
NextCell Pharma Receives OK For Phase II Study On Diabetes Treatment In Children, Adolescents	28/22/28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NextCell Pharma AB

Equities

NXTCL

SE0009723125

Highlights

Filters